House of Commons · Written Ministerial Statement
Strategic Partnership with Oxford Nanopore Technologies
06 November 2024 · Department of Health and Social Care
Proposed by Andrew Gwynne Ind Gorton and Denton
Summarised by AI from the official record, so it can contain mistakes.
At a glance
Key points
- The UK government plans to partner with Oxford Nanopore Technologies to advance biomedical research and patient care.
- The Department of Health and Social Care is working with NHS England, Genomics England, and UK Biobank to implement Oxford Nanopore's technology for genetic testing and pathogen detection in respiratory infections.
- The Respiratory Metagenomics Programme will expand from ten to up to thirty NHS sites.
Issue summary
The UK government plans to enter into a strategic partnership with Oxford Nanopore Technologies to enhance biomedical research and improve patient care.
Action requested
The Department of Health and Social Care is collaborating with Oxford Nanopore, NHS England, Genomics England, and UK Biobank to utilise the company's technology for genetic testing and to detect new pathogens in respiratory infections. The Respiratory Metagenomics Programme will be scaled up from 10 to up to 30 NHS sites.
Key facts
- The partnership involves Oxford Nanopore Technologies, a world-leading UK-based life sciences company.
- The programme aims to diagnose patients with severe acute respiratory infections within six hours using Nanopore’s sequencing technology.
- This initiative supports the shift towards digital health services and prevention in line with the 10-Year Health Plan.